The principle that adoptively transferred T lymphocytes have therapeutic promise for a variety of infections and cancers is established. Recent data from our laboratory and others indicates that human T cell subsets have distinct growth requirements, yet there are no clinically scalable and FDA compliant culture systems for many of the various T cell subsets. For example, it would be desirable to have T cell culture systems that are dedicated to efficient generation of central memory T cells (TCM) or effector T cells (TEM) for cancer and HIV. Similarly, there are no dedicated T cell culture systems to grow regulatory T cells (TREG) to evaluate them as potential therapy for autoimmunity or to prevent organ allograft rejection. Here we assert that limitations in T cell culture technology serve as a barrier to the field of investigators that are developing T cell based immunotherapy strategies. Studies conducted in our laboratory have focused on developing strategies to develop T cell culture systems to mimic the functions of dendritic cells. Our approach has been to develop artificial antigen presenting cells (aAPC) to circumvent the time, expense and sub-optimal reproducibility of dendritic cell cultures. In this project, our overall strategy is to develop novel culture systems based on the concept of artificial antigen presenting cells (aAPC) that we have pioneered. The central hypothesis of this application is that aAPC can be created with efficiency equal to or better than dendritic cells for vaccines and to generate T cell subsets for immunotherapy. In the following three specific aims we will: (1) develop enhanced cell based aAPC by engineering second generation aAPC based on the K562 cell line. (2) test the hypothesis that novel aAPC culture systems will reveal distinct costimulatory and cytokine requirements for long term growth and effector function by human T cell subsets. The culture systems developed in Aim 1 will be used to determine the replicative lifespans of na?ve T cells, TCM, and TEM and (3) adapt cell-based aAPC for clinical use. In preparation for future clinical trials, and so that other laboratories may have access to the cell based aAPC reagents, we will carry out the scale up experiments required to render the cell based aAPC compliant with FDA regulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA105216-03
Application #
7098101
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Howcroft, Thomas K
Project Start
2004-07-01
Project End
2009-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
3
Fiscal Year
2006
Total Cost
$279,000
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunstein, Claudio G; Miller, Jeffrey S; McKenna, David H et al. (2016) Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127:1044-51
Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67
Rapoport, Aaron P; Aqui, Nicole A; Stadtmauer, Edward A et al. (2014) Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 20:1355-65
Grupp, Stephan A; Prak, Eline Luning; Boyer, Jean et al. (2012) Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res 18:6732-41
Ye, Qunrui; Loisiou, Maria; Levine, Bruce L et al. (2011) Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Transl Med 9:131
Brunstein, Claudio G; Miller, Jeffrey S; Cao, Qing et al. (2011) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117:1061-70
Paulos, Chrystal M; June, Carl H (2010) Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest 120:76-80
Paulos, Chrystal M; Carpenito, Carmine; Plesa, Gabriela et al. (2010) The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2:55ra78
Amarnath, Shoba; Costanzo, Carliann M; Mariotti, Jacopo et al. (2010) Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol 8:e1000302
Rapoport, Aaron P; Stadtmauer, Edward A; Aqui, Nicole et al. (2009) Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res 15:4499-507

Showing the most recent 10 out of 29 publications